Category Business

Agenus

Agenus Shows 39% Two-Year Survival with BOT/BAL in Refractory Solid Tumors at ESMO 2025

Agenus Reports Durable Two-Year Survival with BOT/BAL Combination Across Refractory Solid Tumors at ESMO 2025 Agenus Inc. (Nasdaq: AGEN), a biotechnology company recognized for its pioneering work in immuno-oncology, unveiled highly encouraging new clinical data from its novel combination therapy…

Read MoreAgenus Shows 39% Two-Year Survival with BOT/BAL in Refractory Solid Tumors at ESMO 2025

Roche Showcases Breakthroughs in Sequencing by Expansion and Sets New World Record at ASHG 2025

Roche Showcases Breakthrough Sequencing by Expansion (SBX) Technology and Sets New GUINNESS WORLD RECORD™ at ASHG 2025 Roche (SIX: RO, ROG; OTCQX: RHHBY) unveiled a series of groundbreaking advancements in its Sequencing by Expansion (SBX) technology during the American Society…

Read MoreRoche Showcases Breakthroughs in Sequencing by Expansion and Sets New World Record at ASHG 2025

WuXi Biologics Celebrates Sonoma Biotherapeutics’ Fred Ramsdell, PhD, 2025 Nobel Laureate

Transforming Autoimmune and Inflammatory Disease Therapies WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly congratulates Dr. Fred Ramsdell, PhD, co-founder and Chair of the Scientific Advisory Board of its client Sonoma Biotherapeutics, on being…

Read MoreWuXi Biologics Celebrates Sonoma Biotherapeutics’ Fred Ramsdell, PhD, 2025 Nobel Laureate

Zoetis Receives Health Canada Approval for Lenivia® to Treat Osteoarthritis Pain in Dogs

Zoetis Receives Health Canada Approval for Lenivia® to Relieve Osteoarthritis Pain in Dogs Zoetis Inc. today announced that Health Canada has approved Lenivia® (izenivetmab injection) for the treatment of pain associated with osteoarthritis (OA) in dogs. Lenivia, a novel monoclonal…

Read MoreZoetis Receives Health Canada Approval for Lenivia® to Treat Osteoarthritis Pain in Dogs

LEQEMBI® IQLIK™ Autoinjector Named One of TIME’s Best Inventions of 2025

LEQEMBI® IQLIK™ Named One of TIME’s Best Inventions of 2025 for Transforming Alzheimer’s Treatment Access Eisai Co., Ltd. and Biogen Inc. today announced that LEQEMBI® IQLIK™ (lecanemab-irmb), the first subcutaneous autoinjector formulation of the Alzheimer’s disease therapy lecanemab, has been…

Read MoreLEQEMBI® IQLIK™ Autoinjector Named One of TIME’s Best Inventions of 2025

CVS Health® 2025 Rx Report Reveals How Community Pharmacies Are Evolving to Better Serve Patients

CVS Health® 2025 Rx Report Highlights the Evolution of Community Pharmacy to Meet Patient Needs CVS Health® (NYSE: CVS) today unveiled its 2025 Rx Report, Community Pharmacy Reimagined, offering a detailed exploration of how community pharmacies are evolving to meet…

Read MoreCVS Health® 2025 Rx Report Reveals How Community Pharmacies Are Evolving to Better Serve Patients

AstraZeneca Advances Its Mission to Redefine Cancer Care with First Results from Four Pivotal Trials Presented at ESMO 2025

AstraZeneca Showcases Transformative Oncology Pipeline with Breakthrough Data Across Multiple Cancer Types at ESMO 2025 AstraZeneca has reaffirmed its leadership in oncology innovation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, set to take place from October…

Read MoreAstraZeneca Advances Its Mission to Redefine Cancer Care with First Results from Four Pivotal Trials Presented at ESMO 2025